Hsu Wen-Feng, Ladabaum Uri, Su Chiu-Wen, Hsu Chen-Yang, Yen Amy Ming-Fang, Chen Sam Li-Sheng, Hsu Tsui-Hsia, Lin Li-Ju, Lee Yi-Chia, Wu Ming-Shiang, Chen Hsiu-Hsi, Chiu Han-Mo
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
JAMA Netw Open. 2025 Jul 1;8(7):e2523441. doi: 10.1001/jamanetworkopen.2025.23441.
Interval colorectal cancers (CRCs) can occur after a negative result on a primary screening test or after a colonoscopy for a positive screening test result without the diagnosis of CRC.
To compare the burden, incidence, mortality, and long-term survival of interval CRC after a fecal immunochemical test (post-FIT interval CRC) and colonoscopy (postcolonoscopy interval CRC) in the FIT-based Taiwan CRC Screening Program.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed participants (aged 50-74 years) in the Taiwan CRC Screening Program who completed at least 1 FIT between January 1, 2004, and December 31, 2012. Two cohorts were created: one including individuals with a negative FIT result, and the other comprising individuals with a positive FIT result followed by a negative colonoscopy result. Post-FIT interval CRC or postcolonoscopy interval CRC and their survival status were identified and verified via linkage to Taiwan Cancer Registry and Taiwan Death Registry through December 31, 2019. Data analysis was performed between January 2004 and December 2019.
Participants were screened using FIT, with follow-up colonoscopy offered to individuals who tested positive. The main exposures of interest were (1) negative FIT vs positive FIT result with a negative colonoscopy result, and (2) negative FIT and positive FIT results with a negative colonoscopy result further stratified by hospital-level adenoma detection rate (ADR). Low was defined as less than 40% ADR, middle was between 40% and less than 65% ADR, and high was 65% or higher ADR.
The primary outcomes were the incidence, CRC-specific mortality, and survival rates for post-FIT interval CRC and postcolonoscopy interval CRC.
A total of 4018 patients with interval CRC (mean [SD] age at diagnosis, 62.8 [5.9] years; 2118 males [52.7%]) were included in the analysis. Among 15 386 total CRCs in the program, 10 515 (68.3%) were screen-detected CRCs and 4018 (26.2%) were interval CRCs. Of these interval CRC cases, 2782 (18.1%) were post-FIT interval CRCs and 1236 (8.1%) were postcolonoscopy interval CRCs. Compared with post-FIT interval CRC detected after a negative FIT result, postcolonoscopy interval CRC incidence (0.75 [95% CI, 0.71-0.79] per 1000 person-years vs 0.09 [95% CI, 0.09-0.10] per 1000 person-years) and mortality (0.12 [95% CI, 0.11-0.14] per 1000 person-years vs 0.02 [95% CI, 0.02-0.03] per 1000 person-years) after follow-up colonoscopy were higher, with adjusted hazard ratios (AHRs) of 7.06 (95% CI, 6.35-7.57) and 5.04 (95% CI, 4.33-5.85), respectively. Hospital-level ADR was inversely associated with postcolonoscopy interval CRC incidence (high- vs low-ADR group AHR, 0.26; 95% CI, 0.20-0.36) and mortality (AHR, 0.28; 95% CI, 0.19-0.41). However, among patients with postcolonoscopy interval CRC, CRC-specific death was higher in the high-ADR vs low-ADR setting (AHR, 1.89; 95% CI, 1.04-3.43).
This cohort study found that interval CRC incidence and mortality were higher after follow-up colonoscopy than after negative FIT result, which suggests that individuals with a positive FIT result undergoing a colonoscopy exhibit a much higher risk for CRC. Survival after the diagnosis of CRC in the high-ADR subgroup was worse, suggesting a ceiling effect for current colonoscopic techniques and highlighting a possible interplay between procedural and biological factors.
间期结直肠癌(CRC)可在初次筛查试验结果为阴性后发生,或在结肠镜检查筛查试验结果为阳性但未诊断出CRC之后发生。
在基于粪便免疫化学检测(FIT)的台湾结直肠癌筛查项目中,比较粪便免疫化学检测后间期CRC(FIT后间期CRC)和结肠镜检查后间期CRC(结肠镜检查后间期CRC)的负担、发病率、死亡率和长期生存率。
设计、设置和参与者:这项队列研究分析了台湾结直肠癌筛查项目中年龄在50 - 74岁之间、在2004年1月1日至2012年12月31日期间至少完成1次FIT的参与者。创建了两个队列:一个队列包括FIT结果为阴性的个体,另一个队列包括FIT结果为阳性且随后结肠镜检查结果为阴性的个体。通过与台湾癌症登记处和台湾死亡登记处建立联系,确定并验证FIT后间期CRC或结肠镜检查后间期CRC及其生存状态,截至2019年12月31日。数据分析在2004年1月至2019年12月期间进行。
使用FIT对参与者进行筛查,对检测呈阳性的个体提供后续结肠镜检查。主要关注的暴露因素为:(1)FIT结果为阴性与FIT结果为阳性且结肠镜检查结果为阴性,以及(2)FIT结果为阴性和FIT结果为阳性且结肠镜检查结果为阴性,并根据医院层面的腺瘤检出率(ADR)进一步分层。低ADR定义为低于40%,中ADR定义为40%至低于65%,高ADR定义为65%或更高。
主要结局为FIT后间期CRC和结肠镜检查后间期CRC的发病率、CRC特异性死亡率和生存率。
共有4018例间期CRC患者(诊断时的平均[标准差]年龄为62.8[5.9]岁;2118例男性[52.7%])纳入分析。在该项目的15386例结直肠癌中,10515例(68.3%)为筛查发现的结直肠癌,4018例(26.2%)为间期结直肠癌。在这些间期CRC病例中,2782例(18.1%)为FIT后间期CRC,1236例(8.1%)为结肠镜检查后间期CRC。与FIT结果为阴性后检测到的FIT后间期CRC相比,结肠镜检查后间期CRC的发病率(每1000人年0.75[95%CI,0.71 - 0.79] vs每1000人年0.09[95%CI,0.09 - 0.10])和死亡率(每1000人年0.12[95%CI,0.11 - 0.14] vs每1000人年0.02[95%CI,0.02 - 0.03])更高,调整后的风险比(AHR)分别为7.06(95%CI,6.35 - 7.57)和5.04(95%CI,4.33 - 5.85)。医院层面的ADR与结肠镜检查后间期CRC的发病率(高ADR组与低ADR组AHR,0.26;95%CI,0.20 - 0.36)和死亡率(AHR,0.28;95%CI,0.19 - 0.41)呈负相关。然而,在结肠镜检查后间期CRC患者中,高ADR组的CRC特异性死亡高于低ADR组(AHR,1.89;95%CI,1.04 - 3.43)。
这项队列研究发现,结肠镜检查后的间期CRC发病率和死亡率高于FIT结果为阴性后的情况,这表明FIT结果为阳性且接受结肠镜检查的个体患CRC的风险要高得多。高ADR亚组中CRC诊断后的生存率较差,这表明当前结肠镜检查技术存在上限效应,并突出了操作因素和生物学因素之间可能的相互作用。